Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors

J. Feucht & M. Sadelain*

Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

Available online 15 September 2020

T cells engineered to express chimeric antigen receptors (CARs) specific for CD19 have yielded remarkable clinical outcomes in patients with refractory B-cell malignancies. The first CARs to be approved by the US Food and Drug Administration and the European Medicines Agency are CD19 CARs that comprise either CD28/CD3ζ or 4-1BB/CD3ζ dual-signalling domains. While their efficacy and safety profiles in patients with B-cell malignancies are comparable overall, the functional properties of these two CAR designs impart upon engineered T cells differ significantly. Remarkably, alternative costimulatory domains have not, to date, superseded these foundational designs. Rather, recent CAR advances have focused on perfecting the original CD28- and 4-1BB-based CD19 CARs by calibrating strength of activation, pre-empting T-cell exhaustion and increasing the functional persistence of CAR T cells. This article reviews the essential biological properties of these first-in-class prototypes and their recent evolution.

Key words: cancer immunotherapy, CAR therapy, CD19, CD28, 4-1BB, chimeric antigen receptors, immune-oncology

INTRODUCTION

Chimeric antigen receptors (CARs) are synthetic receptors that reprogram the specificity, phenotype and functions of immune cells. Early fusion receptors that combined an extracellular antigen-binding moiety derived from an antibody with a T-cell activating domain, later referred to as ‘first-generation CARs’, redirected the cytolysis of T-cell lines or hybridomas but could not sustain the function of primary T cells. The integration of activating and costimulatory functionalities within a single receptor for antigen, yielding ‘second-generation CARs’, enabled human peripheral blood T cells to not only lyse their targets but expand upon repeated exposure to antigen. Focusing on CD19 as a promising CAR target, second-generation CARs encoding either CD28 or 4-1BB costimulatory domains were approved by the US Food and Drug Administration (FDA) in 2017 and the European Medicines Agency in 2018 for the treatment of relapsed/refractory non-Hodgkin lymphoma and acute lymphoblastic leukaemia (ALL). Several reviews that address the clinical results of CAR therapy trials targeting CD19 using engineered T cells or natural killer (NK) cells are available.

There are currently over 500 CAR trials worldwide registered at clinicaltrials.gov, with more than 230 targeting CD19. Second-generation CARs using either CD28 or 4-1BB costimulatory domains account for approximately 80% of the investigated CAR designs.

In the context of B-cell malignancies, 28ζ and BBζ CARs targeting CD19 (hereafter referred to as ‘19CD28ζ’ and ‘19BBζ’) have achieved overall comparable therapeutic efficacy. Due to rapidly increasing clinical experience, the major challenges of CD19 CAR therapy, irrespective of the costimulatory component, have become evident, including a significant relapse rate despite remarkable initial response to therapy and treatment-associated toxicities. Tumour relapses have been associated with insufficient T-cell persistence, dysfunctional T-cell states, and antigen escape with absent or low-level antigen expression. The two most severe toxicities caused by CAR T-cell therapy include cytokine release syndrome (CRS), which is characterized by elevated fever, hypotension and hypoxia associated with abundant release of pro-inflammatory cytokines, and immune effector cell-associated neurotoxicity syndrome (ICANS), which has been associated with endothelial dysfunction, increased permeability of the blood–brain barrier and microglial activation.

Preclinical and clinical studies have revealed important differences in the properties imparted by 28ζ and BBζ CARs on T cells. The detailed investigation of their respective features, together with an ever-progressing understanding of intrinsic and extrinsic determinants that promote
T-cell-mediated tumour immunity, instruct the development of novel CAR T-cell designs at a rapid pace. This review will summarize current knowledge on the foundational 28ζ and BBζ CARs themselves and their respective evolution. Complementary efforts to enhance CAR T cells, including improvements in the manufacturing process, the selection of T-cell subsets and CD4/CD8 ratios, combinatorial targeting and logic gating strategies, armoured CARs and safety switches, are beyond the scope of this review.

CD28 AND 4-1BB RECEPTORS IN NATURAL T-CELL RESPONSES

The ligation of the physiological T-cell receptor (TCR) with cognate peptide—major histocompatibility complexes initiates T-cell activation, but naïve T cells require costimulation to prevent T-cell unresponsiveness and mount an effective response.25–27 The immunoglobulin superfamily member CD28 and the tumour necrosis factor receptor superclass member 4-1BB are the two main costimulatory receptors to have been originally co-opted within second-generation CAR T cells.23,28

CD28 engagement by its ligands CD80 or CD86 expressed in antigen-presenting cells (APCs) initiates signal transduction events that affect a variety of T-cell processes.28,29 CD28 costimulation augments signals generated by TCR ligation, lowers the threshold for naïve T-cell activation,25,26 and recruits the PI3K-AKT pathway and the transcription factors NF-κB, NFAT and AP1 to regulate cell proliferation, survival, effector function and differentiation.26,27 In addition, CD28 signalling upregulates the expression of several cytokines and chemokines, most significantly interleukin-2 (II-2); increases glucose uptake upon T-cell activation; and induces epigenetic changes that are required for commitment to cell growth, cell-cycle entry and differentiation.25–27,29 Lack of CD28 costimulation is associated with decreased T-cell proliferation and differentiation, inhibition of germinal centre formation and repressed cytokine expression, coinciding with reduced responses to a wide spectrum of immune challenges in CD28-deficient mice.28,30

4-1BB (CD137) is induced transiently by TCR and CD28 signalling in CD4+ and CD8+ T cells and binds to its ligand 4-1BBL (CD137L) expressed in APCs and activated T cells.28 4-1BB ligation transmits signalling via recruitment of TNF-receptor-associated factor (TRAF) proteins, leading to activation of the PI3K/AKT, stress-activated protein kinase/JNK, p38 MAPK, ERK1/2 and NF-κB pathways.28,31 4-1BB-mediated signalling promotes mitochondrial function and biogenesis in T cells; augments T-cell survival; and enhances cytokine production, proliferation and memory formation.28,32 Mice deficient in 4-1BB show diminished CD8+ T-cell responses with decreased cytolytic activity and cytokine secretion, as well as a reduced CD8+ memory pool.28,33

ESSENTIAL FUNCTIONAL CHARACTERISTICS OF 28ζ AND BBζ CAR T CELLS

The combinatorial structure of CARs (Figure 1) determines unique spatial and temporal constraints that warrant close examination of the properties these synthetic molecules impart on T-cell subsets. 28ζ CAR T cells have been shown to possess potent effector functions, associated with robust cytokine secretion and effector differentiation following antigen encounter and relatively rapid tumour elimination.28,34–39 In comparison, BBζ CAR T cells show a slower effector response but greater T-cell persistence.34,40,41 In accordance with the metabolic features of their costimulatory receptor of origin,12,42,43 the high effector functions of 28ζ CAR T cells are associated with increased aerobic glycolysis, while BBζ CAR T cells show greater mitochondrial biogenesis and oxidative metabolism.41

1928ζ CAR T cells mediate more rapid tumour eradication in several aggressive leukaemia and lymphoma mouse models, including ‘stress test conditions’ based on the administration of low T-cell doses, compared to 19BBζ.21,34,36,39,44 However, 19BBζ CAR T cells accumulate to increased numbers over time, compensating through their durability for their slighter cytolytic capabilities on a single cell basis.21,34 These findings in mouse models are corroborated in clinical trials that report earlier clearance of 1928ζ45–47 CAR T cells relative to 19BBζ CAR T cells. The latter can be detected in some patients for months and even years.15,48–50

Although side-by-side comparative studies are lacking in patients, the capability of both CAR constructs to achieve efficient tumour control and similar response rates overall, in spite of the distinct kinetics of tumour eradication and T-cell accumulation, is reflected in multiple clinical trials reported to date.14,15 While CAR T-cell persistence is an important correlate of long-term remission in 19BBζ-treated patients, such persistence does not seem to be an essential prerequisite for durable responses induced by 1928ζ.36,46,50–52 The lesser correlation between CAR T-cell persistence and survival in 1928ζ-treated patients indicates that this CAR design can induce sustained remissions on the strength of rapid responses without obligate persistence.36,45,46 Thus, persistence becomes an increasingly important requirement for T cells with more modest intrinsic effector potential. The contribution of T-cell persistence should also be evaluated with caution, not only through the mere presence of CAR T cells, but by assessing the functionality of those persisting T cells, such as their capability for memory formation, rapid re-expansion and protection against tumour rechallenge or prevention of endogenous relapse. Some poor responses to 19BBζ CAR T-cell therapy have been linked to impaired T-cell states in preclinical and clinical studies, highlighting the importance of evaluating functional persistence, not mere T-cell survival.41,53,54

T-CELL EXHAUSTION AND TONIC SIGNALLING IN CAR T CELLS

T-cell exhaustion is a functional state characterized by diminished effector function, hypo-responsiveness to antigen, and an altered transcriptional and epigenetic profile.55–57 Exhausted T cells typically co-express multiple
inhibitory receptors, such as PD1, TIM3, LAG3, CTLA4 and/or TIGIT, and exhibit a reduced Tbet/EOMES ratio. CAR T-cell dysfunction due to T-cell exhaustion is an important limitation of both CD28ζ and BBζ CAR T cells. CAR-induced exhaustion should be distinguished from a pre-existing condition in patient T cells present upon their collection or reduced functionality secondary to suboptimal culture conditions, all of which may contribute to impaired T-cell quality.

Increased expression of exhaustion markers appears earlier in infused 1928ζ CAR T cells compared to 19BBζ. This phenotypic difference has been attributed to the strong activation mediated by CD28ζ CARs, driving rapid T-cell differentiation and high effector function preceding T-cell contraction. T-cell dysfunction also occurs in 19BBζ CAR T cells and has been associated with poor clinical responses and tumour escape in murine models. Progressive functional impairment of 19BBζ CAR T cells with concomitant transcriptional and epigenetic reprogramming is further observed upon persistent antigen stimulation by death-receptor-dysregulated leukaemia cells.

While T-cell exhaustion may arise following repeated exposure to antigen, CARs can produce antigen-independent or tonic signalling which promotes T-cell expansion and also induces premature T-cell dysfunction, impairing antitumour activity. T-cell dysfunction occurring in the absence of cognate antigen is a general phenomenon observed with different CAR designs. In some settings, it may occur faster in 28ζ CAR T cells, but tonic signalling does not only depend on the costimulatory moiety of the CAR. Other contributing factors involve CAR expression levels, vector type and copy number, promotor strength, as well as other CAR structural components including the scFv (e.g. prone to spontaneous oligomerization), the CD3ζ chain or the selection of hinge/transmembrane (H/TM) domains. For example, T-cell exhaustion triggered by tonic signalling was observed in CAR T cells targeting the disialoganglioside GD2, but was not detected in CD19 CAR T cells, independent of 4-1BB or CD28 costimulation. Other studies have observed antigen-independent signalling in 19BBζ CAR T cells, albeit with differences in the underlying signalling pathways. Tonic CAR-derived 4-1BB signalling may be amplified in gammaretroviral vectors through continuous activation of the NF-κB pathway, which enhances LTR promoter activity and, in turn, amplifies CAR expression and tonic signalling. Attenuated CAR expression can mitigate these effects and augment therapeutic potency. Importantly, controlling transcription of the CARs by means of genome editing can abate tonic signalling and T-cell exhaustion, resulting in improved antitumour efficacy.
TUMOUR RELAPSE AND ANTIGEN SENSITIVITY

Similar to other targeted immunotherapies such as monoclonal or bispecific T-cell-engager antibodies, antigen modulation on tumour cells can impede therapeutic efficacy of CAR T cells. Tumour escape with variants expressing stable CD19 antigen expression, in which CARs costimulatory component and its target sensitivity below a certain threshold impedes in vivo antitumour efficacy of both 1928 and 19BB in vivo. Several studies indicate that the costimulatory composition of CARs contributes to determining CAR sensitivity to low levels of target antigen. CAR T cells incorporating CD28 generally have higher activity against tumour cells with low antigen levels compared to BB-based CARs, which are more vulnerable to antigen downregulation.

The differential antigen sensitivity of 1928 and 19BB CAR T cells was demonstrated in an experimental relapse model using the B-ALL cell line NALM6, in which antigen reduction resulted from trogocytic transfer of the CD19 antigen from the malignant cells to T cells, thereby reducing the antigen density on the remaining target cells. 1928 CAR T cells showed improved control of relapses compared with 19BB, resulting in enhanced survival of mice rescued with 1928 CAR T cells. The higher antigen sensitivity threshold of 19BB CAR T cells was confirmed in models using stable CD19 antigen expression, in which 1928 CAR T cells outperformed 19BB CAR T cells at low antigen levels and significantly prolonged survival of treated mice.

1928 CAR T cells killed efficiently, proliferated robustly and produced IL-2 in response to antigen-low leukemia cells, in contrast to 19BB CAR T cells which exhibited lesser responses. The observed differences were linked to a more rapid tumour lysis in 1928 T-cell-target cell conjugates and to increased signalling strength observed with 1928 CAR T cells. The lower antigen expression levels required for effective antitumour activity of CD28-based CARs were further linked to their increased basal CD3 phosphorylation owing to LCK recruitment into the CAR synapse, imprinting 1928 CAR T cells to a higher magnitude of activity in response to low antigen stimulation, whereas CAR-CD3 phosphorylation in BB-based CARs has been shown to be negatively regulated by the THEMIS—SHP1 complex.

Together, these findings establish a link between the CAR’s costimulatory component and its target sensitivity (i.e. the target antigen density required for effective tumour elimination). This observation points to the importance of monitoring antigen density in tumour escape specimens, and clearly delineating antigen-negative versus antigen-low relapses.

SIGNALLING OF 1928 AND 19BB CARs

Mass spectrometry analyses have revealed that protein phosphorylation events activated by the stimulation of CD28- and 4-1BB-based CAR T cells are highly similar. Major differences in T-cell fates observed between CD28- and 4-1BB-based CAR T cells were linked to changes in the kinetics and magnitude of protein phosphorylation after activation rather than to specific/unique signalling pathways triggered by each costimulatory element. The faster and more intense phosphoprotein signals induced by CD28 compared with 4-1BB costimulation were associated with an effector-like T-cell phenotype, and the elevated signal intensity in CD28-based CARs was partly related to a greater constitutive association of LCK with this domain. Expanding on this finding, a recent study has demonstrated that CD28 and 4-1BB regulate the equilibrium of kinases and phosphatases differentially within the CAR synapse, thereby determining the magnitude of CAR T-cell activation.

Pharmacological inhibition of the PI3K/AKT axis limits glycolytic metabolism and T-cell differentiation in 1928 CAR T cells, pointing towards an important role of this signalling pathway in CD28-based CAR T cells. NF-kB has been identified as a critical signalling pathway for 19BB CAR T cells, and the functionality of 4-1BB within CARs is in part mediated by specific TRAF proteins to activate NF-kB. Moreover, specific interrogation of the non-canonical (nc) NF-kB pathway has indicated that 19BB CAR T cells exhibit constitutive and higher ligand-induced nNF-kB signalling compared with 1928 CAR T cells. nNF-kB signalling was required to promote cell survival in 19BB CAR T cells and was associated with reduced abundance of the most pro-apoptotic isoforms of Bim. Much still remains to be elucidated with regards to 28 and BB CAR signalling.

STRATEGIES TO IMPROVE CD28 CARs

One approach to increase the therapeutic efficacy of 1928 CAR T cells is to extend their functional persistence (Figure 2). Given the redundancy of CD28 and CD3 chains, we hypothesized that signalling strength may be excessive and thus calibrated down the CAR activation potential by mutating immune-tyrosine-based activation (ITAM) motifs in the CD3 chain. 1928 CAR T cells bearing only two functional ITAMs in membrane-proximal position, termed ‘1928-1XX’, outperformed conventional 1928 CAR T cells under stress test conditions in a murine leukaemia model in vivo. In contrast to the short-lived 1928 CAR T cells, which may differentiate rapidly and acquire an exhausted phenotype, 1928-1XX CAR T cells show increased persistence in a functional state, resulting in long-term T-cell memory and resistance to multiple tumour rechallenges.
Studies focusing on the length and composition of the H/TM domain have shown that CD19 CARs with a CD8 H/TM domain display reduced cytokine secretion, decreased T-cell activation and less susceptibility to activation-induced cell death compared with CARs incorporating CD28 H/TM domains, albeit displaying inferior antitumour activity in disseminated leukaemia models. In a phase 1 clinical trial in patients with B-cell lymphoma, CD8a(H/TM)-28z CAR T-cell therapy showed comparable antitumour efficacy as the commercial FMC63-28z CAR, but suggested increased CAR T-cell persistence and lower incidence of neurologic toxicities. Longer patient follow-up is needed to determine if CD8a(H/TM)-28z CAR T cells retain high therapeutic efficacy.

Other approaches have aimed to alter the signalling of 28z CARs by mutating the CD28 signalling domain. Modifications in the CD28 PYAPP motif to disrupt LCK binding decreased IL-2 secretion upon CAR engagement, without impairing proliferation and cytotoxicity. Another single amino acid mutation in the YMNM motif of CD28, turning it into the YMFM motif of ICOS, a CD28-like costimulatory receptor, mediated a transcriptional signature associated with reduced T-cell differentiation and exhaustion, resulting in enhanced CAR T-cell persistence and antitumour activity.

The enhanced persistence and augmented cytokine polyfunctionality of engineered T cells with increased JAK-STAT signalling will require cautious evaluation of potential toxicities.

**STRAIGHTS TO IMPROVE BBz CARs**

While reducing the CAR activation potential by mutating ITAMs in the CD3z signalling domain has been shown to be

---

Figure 2. Engineering strategies to improve 1928z and 19BBz chimeric antigen receptors (CARs).

(a) Approaches to overcome limitations of CD28z-based CAR T cells. (b) Strategies to improve functionality of BBz-based CAR T cells. Recent developments are focused on tuning strength of activation, reversing exhaustion, enhancing functional persistence, and combining features of both CAR prototypes by enhancing memory formation in 1928z CAR T cells and enhancing the effector function of 19BBz CAR T cells.
a successful strategy to extend the persistence of 1928zCAR T cells,35 4-1BBzCAR T cells may, on the contrary, benefit from signalling augmentation to boost their performance. Inclusion of additional ITAMs to augment activating strength can indeed increase the functionality of less potent 19BBzCAR T cells (Figure 2). Incorporating two copies of the CD3z chain in 19BBzCAR T cells, yielding 12 ITAMs per CAR, enhanced antigen sensitivity, increased IL-2 secretion and improved antitumour activity in response to target cells with low CD19 density relative to 19BBzCAR T cells, but still with inferior antitumour activity compared with 1928zCAR T cells.34 LCK overexpression in 19BBzCAR T cells was associated with increased basal phosphorylation of CAR-CD3z and also resulted in improved antitumour activity compared with 19BBzCAR T cells, without diminishing the potential for increased persistence.38 NF-κB signalling, which plays an essential role in 4-1BB costimulation, also promotes increased CAR T-cell proliferation. 19BBzCAR T cells with mutated TRAF binding domains displayed reduced NF-κB signalling and attenuated T-cell function. Conversely, modulation of NFKB signalling through overexpression of TRAF proteins can enhance antitumour T-cell activity. Thus, 19BBzCAR T cells that overexpress TRAF2 or TRAF3 display increased viability, proliferation and cytotoxicity function in vitro. However, 19BBzCAR T cells with excess TRAF2 did not reach superior antitumour activity in vivo compared with 19BBzCAR T cells.36 The optimization of TRAF recruitment may thus have the potential to enhance CAR T-cell function but requires further investigation.36 Blockade of TGF-β signalling enhances 4-1BB-mediated T-cell function as demonstrated by improved antitumour activity induced by a chimeric TGF-βR2-41BB receptor.85 On the other hand, 28zCAR T cells are intrinsically resistant to TGF-β repression relative to BBzCARs.86

Similar to 28zCARs,87 alterations in the H/TM region can impact T-cell effector function in 19BBzCAR T cells.88 Substitution of a CD8 H/TM domain with the 28H H/TM region from 1928zCARs resulted in increased cytokine production and enhanced antitumour activity of 19BBzCAR T cells, especially at low CD19 expression levels.84 In a recent phase I clinical trial with 19BBzCAR T cells, in which the length of the CD8α H/TM domain was modified to potentially reduce toxicities,87 19BBz(86) variant CAR T cells comprising an 86-amino-acid fragment from human CD8α with a longer extracellular domain and a longer intracellular sequence compared with the 19BBz(71) prototype, reduced CRS and neurological toxicities after treatment with 19BBz(86) CAR T cells while therapeutic responses were effective.87 Further studies are needed to ascertain that therapeutic efficacy induced by 19BBz(86) is not impaired.

Other efforts to improve 4-1BBz-based CAR T cells have focused on CAR binding affinity. 19BBzCAR T cells incorporating a lower-affinity scFv with a faster off-rate (CAT CARs) than the FMC63 high-affinity binder used in FDA-approved CD19 CAR T cells were evaluated in paediatric patients and young adults with high-risk B-ALL.88 Initial responses and survival rates were comparable to historical CD19 CAR trials in ALL, but associated with enhanced expansion and persistence of CAR T cells without severe CRS or ICANS. These lesser toxicities have to be interpreted with caution due to low tumour burden before treatment, which is generally associated with reduced risk for severe CRS.89 Here too, the efficacy and durability of responses will have to be assessed with longer follow-up.

**GENERAL APPROACHES TO ENHANCE BOTH 28z AND BBzCAR T CELLS**

There are other potential improvements to CAR function that apply to both 28z and BBzCARs (Figure 3).

The genomic integration site of the CAR cDNA plays a central role in determining the phenotype and function of CAR T cells. Controlled CAR expression through targeted insertion of the 1928zCAR cDNA in the TRAC locus using CRISPR/Cas9 results in uniform CAR expression levels and distinct patterns of antigen-induced CAR internalization and re-expression in comparison to retrovirally engineered CAR T cells. TRAC-CAR T cells exhibit reduced tonic signalling, delayed T-cell exhaustion, differentiation and enhanced antitumour activity relative to conventionally engineered CAR T cells.66 Similarly, TRAC-19BBzCAR T cells yield constant CAR expression and achieve superior tumour eradication in vivo.66 Transcriptional and epigenetic alterations associated with T-cell exhaustion include epigenomic dysregulation of AP-1 transcription factor binding motifs and increased expression of the bZIP and IRF transcription factors, which have been implicated in mediating T-cell dysfunction.55 Overexpression of the activating AP-1 family transcription factor c-Jun in CD28zCAR- or 4-1BBz-based CAR T cells establishes a more propitious balance between activating and inhibitory AP-1 complexes.55 To prevent T-cell exhaustion in CD28z-based CARs, further efforts have involved genetic targeting of transcription factors driving T-cell exhaustion,90,91 such as the high-mobility group-box transcription factors TOX and TOX2; and the members of the NR4A family of nuclear receptor transcription factors Nrf4a1, Nrf4a2 and Nrf4a3.1928zCAR T cells lacking all three Nrf4a transcription factors promoted improved tumour regression and prolonged survival of CD19+ tumour-bearing mice relative to 19BBzwild-type CAR T cells in murine models. The enhanced effector function of Nrf4a triple knockout CAR T cells was associated with increased cytokine production, downregulation of inhibitory receptors, and strong enrichment in accessible chromatin for binding motifs of transcription factors involved in effector function.91 1928zCAR T cells double deficient in TOX and TOX2 showed reduced expression of T-cell exhaustion markers, higher cytokine secretion, and displayed transcriptional and epigenetic alterations associated with T-cell activation and effector function, resulting in enhanced antitumour effects in vivo.90,91

CRISPR-Cas9-mediated disruption of the inhibitory molecules PD-1 or LAG3 has been investigated as a strategy to prevent T-cell dysfunction in 19BBzCAR T cells,92,93 and
deletion of the \textit{Pdcd1} (PD-1) locus in 19BB\textsubscript{z} CAR T cells resulted in enhanced \textit{in vivo} antitumour activity against PD-L1\textsuperscript{+} tumours.\textsuperscript{93} Further gene-editing approaches that are currently evaluated involve multiplex genome editing targeting TCR, \(\beta_2\)-microglobulin and Fas, PD-1 and CTLA-4 or other molecules to promote efficacy and more universal applicability of CD19 CAR T cells.\textsuperscript{94–96} Deletion of REGNASE-1 in CD8\textsuperscript{+} 19BB\textsubscript{z} CAR T cells reprogrammed T cells in the tumour microenvironment to long-lived effector cells by enhancing mitochondrial metabolism and effector responses.\textsuperscript{97} Previous findings further demonstrated improved functionality of PTPN2-deleted CAR T cells in solid tumour models.\textsuperscript{98} The ablation of the histone methyltransferase Suv39h1 was shown to enhance long-term memory and functionality in murine CD8\textsuperscript{+} T cells.\textsuperscript{99} These latter findings open novel perspectives for epigenetic reprogramming of CAR T cells.

Clinical experience with gene-edited T cells is still very limited. Cautious interrogation of efficacy and safety risks, changes in the manufacturing process, and identification of
host factors influencing therapeutic potency are required for their successful clinical translation.

CONCLUSIONS

The incorporation of costimulatory molecules in the design of synthetic receptors for antigen paved the way for the success of CD19 CAR therapy and the advent of ‘living drugs’. 1928 and 19BB CARs are the most frequently investigated CAR T-cell constructs worldwide. Their unprecedented success has laid the foundation for a global increase in CAR T-cell clinical trials. While overall comparable efficacy has been reported for 1928 and 19BB CARs across different B-cell malignancies, the combination of activating and costimulatory signals can be finely tuned to modulate CAR T-cell effector functions and persistence. A deepening understanding of how CARs work will enable the design of better and safer therapies. It is noteworthy that while many other natural costimulatory signalling domains are available and easy to incorporate into a CAR structure, the most profound recent insights into CAR T-cell biology come from detailed studies of the functional properties of the canonical 28 and BB CAR T cells — in vitro, in xenogeneic murine models and in clinical trial correlative studies. The development of tumour models that recapitulate the human diseases, including patient-derived xenograft models and human-derived organoids, should further accelerate the testing and comparison of different CAR T-cell products. Complementing these analyses and the rapid development of novel CAR designs, the use of genome editing, still limited in clinical practice, is poised to further advance the design of CAR T cells for a wide range of medical applications.

FUNDING

This work was supported by the Memorial Sloan Kettering Cancer Center Support Grant [P30 CA008748]. J.F. was supported by the Care-for-Rare Foundation and the German Research Foundation.

DISCLOSURE

M.S. reports research funding from Fate Therapeutics, Takeda Pharmaceuticals and Atara Biotherapeutics. M.S. serves on the Scientific Advisory Board of St Jude Children Research Hospital. M.S. and J.F. hold several patents on CAR technologies.

REFERENCES

1. Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423–431.
2. Esthcar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytolytic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724.
3. Brocker T, Peter A, Trauender A, Karjalainen K. New simplified molecular design for functional T cell receptor. Eur J Immunol. 1993;23(7):1435–1439.
4. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215–223.
5. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1(2):123–127.
6. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCReza /CD28 receptor. Nat Biotechnol. 2002;20(1):70–75.
7. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3):279–286.
8. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676–684.
9. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.
10. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31–46.
11. Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood. 2018;131(24):2621–2629.
12. Jain MD, Davila ML. Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell malignancies. Stem Cells. 2018;36(1):36–44.
13. Tanaka J, Miller JS. Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Rev. 2020;100678.
14. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586–1594.
15. Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25(9):1341–1355.
16. Mackay M, Afshinnekoo E, Rub J, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–244.
17. Guedan S, Calderon H, Posey Jr AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145–156.
18. Santomasso B, Bacher C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433–444.
19. Shah NN, Fry TJ. Mechanisms of resistance to CAR T-cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385.
20. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–1226.
21. Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and critically lyse prostate cancer cells. Proc Natl Acad Sci U S A. 2020;117(1):244.
22. Singh N, Orlando E, Xu J, et al. Mechanisms of resistance to CAR T cell therapy. Semin Cancer Biol. 2020;65:91–98.
23. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–1419.
24. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. T-cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–738.
25. Boomser JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010;2(8):a002436.
26. Acuto O, Michel F. CD28-meditated co-stimulation: a quantitative support for TCR signaling. Nat Rev Immunol. 2003;3(12):939–951.
27. Chen L, Fries DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242.
28. van der Stegen S, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499–509.
Immuno-Oncology Technology

J. Feucht & M. Sadelain

29. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. *Immunity*. 2016;44(5):973–988.

30. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. *Science*. 1999;261(5152):609–612.

31. Ward-Kavanagh LK, Lin WW, Sedy JR, Ware CF. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. *Immunity*. 2016;44(5):1005–1019.

32. Menk AV, Scharping NE, Rivadeneira DB, et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. *J Exp Med*. 2018;215(4):1091–1100.

33. Kwon BS, Hurtado JC, Lee ZH, et al. Immune responses in 4-1BB (CD137)-deficient mice. *J Immunol*. 2002;168(11):5483–5490.

34. Zhao Z, Condomines M, van der Stegen SJ, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. *Cancer Cell*. 2015;28(4):415–428.

35. Feucht J, Sun J, Eyquem J, et al. Calibration of CAR activation potential directly affects alternative T cell fates and therapeutic potency. *Nat Med*. 2019;25(1):82–88.

36. Li G, Boucher JC, Kotani H, et al. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. *JCI Insight*. 2018;3(18).

37. Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. *Sci Signal*. 2018;11(544).

38. Sun C, Shou P, Du H, et al. THEMIS-SHP1 recruitment by 4-1BB tunes LC-skewed priming of chimeric antigen receptor-redirected T cells. *Cancer Cell*. 2020;37(2):216–225.e6.

39. Cheng Z, Wei R, Ma Q, et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. *Mol Ther*. 2018;26(4):976–985.

40. Philippson BI, O’Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB-dependent signaling. *Sci Signal*. 2020;13(625).

41. Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. *Immunity*. 2016;44(2):380–390.

42. Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. *Immunity*. 2002;16(6):769–777.

43. Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in CD28-decient mice. *Science*. 1999;261(5152):609–612.

44. Philip M, Schietinger A. Heterogeneity and fate choice: T cell immunity. *J Immunol*. 2015;196(1):665–674.

45. Wherry EJ. T cell exhaustion. *Nat Rev Immunol*. 2011;11(2):492–499.

46. Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR expressing CD137-deleted T cells. *Cancer Immunol Res*. 2018;6(9):1038–1038.e1.

47. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance for CD19 chimeric antigen receptor (CAR) T cell therapy of B-cell acute lymphoblastic leukemia. *J Immunol*. 2019;191(11):665–674.

48. Alabanza L, Pegues M, Geldres C, et al. Function of novel anti-CD19 monoclonal antibodies in neutralizing CD19 CAR-T cells and increased antileukemic efficacy in vivo. *Mol Ther*. 2018;26(4):976–985.

49. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the CD28 signaling pathway reveals an alternative mechanism for CAR T cell activity. *J Immunother*. 2019;42(6):298–305.

50. Philip M, Schietinger A. Heterogeneity and fate choice: T cell immunity. *J Immunol*. 2015;196(1):665–674.

51. Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. *Cancer Immunol Res*. 2015;3(4):356–367.

52. Ajina A, Maher J. Strategies to address chimeric antigen receptor (CAR) T cell longevity and persistence of CAR T cells. *Cancer Immunol Res*. 2018;6(9):1100–1109.

53. Li G, Boucher JC, Kotani H, et al. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. *JCI Insight*. 2018;3(18).

54. Singh N, Lee YG, Shestova O, et al. Impaired death receptor signaling induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. *J Exp Med*. 2018;215(4):1091–1100.

55. Lynn RC, Weber EW, Sotillo E, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. *Nature*. 2019;576(7786):293–300.

56. Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. *Nat Rev Immunol*. 2019;19(11):665–674.

57. Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. *Immunity*. 2002;16(6):769–777.

58. Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. *J Immunol*. 2008;180(7):4476–4486.

59. Majerger RG, Rietberg SP, Sotillo E, et al. Tuning the antigen density requirement for CAR T cell activity. *Cancer Discov*. 2020;10(5):702–723.

60. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing 4-1BB chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial. *Lancet*. 2015;385(9967):517–528.

61. Park JH, Riveri E, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):449–459.

62. Davila ML, Riveri E, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*. 2014;6(224):224ra225.

63. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 2014;371(16):1507–1517.

64. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):439–448.

65. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med*. 2018;24(5):563–571.

66. Mueller KT, Waldron E, Grupp SA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. *Clin Cancer Res*. 2018;24(24):6175–6184.

67. Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. *J Clin Invest*. 2019;129(5):2123–2132.
77. Priceman SJ, Gerds TA, Tilakawardane D, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCAþ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764.

78. Ramello MC, Benzaid I, Kuenzi BM, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019;12(568).

79. Klebanoff CA, Crompton JG, Leonardi AJ, et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight. 2017;2(23).

80. Hudecek M, Sommermeyer D, Kosasih PL, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–135.

81. Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270–280.

82. Koffler DM, Chmielewski M, Rapp G, et al. CD28 costimulation impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther. 2011;19(4):760–767.

83. Guedan S, Madar A, Casado-Medrano V, et al. Single residue in CD28-zeta CAR T cells targeting PSCAþ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764.

84. Kagoya Y, Tanaka S, Guo T, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352–359.

85. Roth TL, Li PJ, Blaesche F, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell. 2020;181(3):728–744.e1.

86. Golumba-Nagy V, Kuehle J, Hombach AA, Abken H. CD28-zeta CAR T cells resist TGF-beta repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Mol Ther. 2018;26(9):2218–2230.

87. Ying Z, Huang XF, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947–953.

88. Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408–1414.

89. Brentjens RI, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138.

90. Seo H, Chen J, Gonzalez-Avalos E, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(þ) T cell exhaustion. Proc Natl Acad Sci U S A. 2019;116(25):12410–12415.

91. Chen J, Lopez-Moyado IF, Seo H, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530–534.

92. Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11(4):554–562.

93. Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.

94. Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8(10):17002–17011.

95. Qasim W, Zhan H, Samarasinge S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374).

96. Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853–3864.

97. Wei J, Long L, Zheng W, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576(7787):471–476.

98. Wiede F, Lu KH, Du X, et al. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. EMBO J. 2020;39(2):e103637.

99. Pace L, Goudot C, Zueva E, et al. The epigenetic control of stemness in T cells. J Immunol. 2017;198(11):4711–4718.

100. Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481).